FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385476503> ?p ?o ?g. }

• W4385476503 abstract "Abstract Background Rare primary malignant bone sarcomas (RPMBS) account for 5%–10% of primary high‐grade bone tumors and represent a major treatment challenge. The outcome of patients with RPMBS enrolled in the EUROpean Bone Over 40 Sarcoma Study (EURO‐B.O.S.S) is presented. Methods Inclusion criteria were as follows: age from 41 to 65 years and a diagnosis of high‐grade spindle cell, pleomorphic, or vascular RPMBS. The chemotherapy regimen included doxorubicin 60 mg/m 2 , ifosfamide 9 g/m 2 , and cisplatin 90 mg/m 2 ; postoperative methotrexate 8 g/m 2 was added in case of a poor histologic response. Version 2.0 of the Common Terminology Criteria for Adverse Events, Kaplan–Meier curves, log‐rank tests, and univariate Cox regression models were used. Results In total, 113 patients were evaluable for analysis. The median patient age was 52 years (range, 40–66 years), and 67 patients were men. Eighty‐eight tumors were categorized as undifferentiated pleomorphic sarcomas (UPS), 20 were categorized as leiomyosarcomas, three were categorized as fibrosarcomas, and two were categorized as angiosarcomas. Eighty‐three of 113 tumors were located in the extremities. Ninety‐five of 113 patients presented with no evidence of metastases. After a median follow‐up of 6.8 years (interquartile range [IQR], 3.5–9.8 years), the 5‐year overall survival rate for patients with localized disease was 68.4% (IQR, 56.9%–77.5%), and it was 71.7% (IQR, 58.1%–81.6%) for patients with UPS and 54.9% (IQR, 29.5%–74.5%) for patients with leiomyosarcoma. Grade III–IV hematologic toxicity was reported in 81% patients; 23% had grade II–III neurotoxicity, and 37.5% had grade I–II nephrotoxicity. Five‐year overall survival was significantly better for patients with localized disease, for patients who obtained surgical complete remission, and when the primary tumor was located in the extremities. Conclusions The survival of patients who had RPMBS in the current series was similar to that of age‐matched patients who had high‐grade osteosarcoma treated according to the same protocol. An osteosarcoma‐like chemotherapy may be proposed in patients who have RPMBS." @default.
• W4385476503 created "2023-08-03" @default.
• W4385476503 creator A5010518603 @default.
• W4385476503 creator A5022611419 @default.
• W4385476503 creator A5027746254 @default.
• W4385476503 creator A5033483931 @default.
• W4385476503 creator A5034299376 @default.
• W4385476503 creator A5035939033 @default.
• W4385476503 creator A5037999437 @default.
• W4385476503 creator A5042712372 @default.
• W4385476503 creator A5048170384 @default.
• W4385476503 creator A5050243008 @default.
• W4385476503 creator A5050932223 @default.
• W4385476503 creator A5077916842 @default.
• W4385476503 creator A5080548972 @default.
• W4385476503 creator A5082008325 @default.
• W4385476503 creator A5084241424 @default.
• W4385476503 creator A5086814670 @default.
• W4385476503 creator A5090145105 @default.
• W4385476503 creator A5091533961 @default.
• W4385476503 date "2023-08-02" @default.
• W4385476503 modified "2023-10-17" @default.
• W4385476503 title "Outcome of rare primary malignant bone sarcoma (RPMBS) treated with multimodal therapy: Results from the EUROpean Bone Over 40 Sarcoma Study (EURO‐B.O.S.S)" @default.
• W4385476503 cites W1846976861 @default.
• W4385476503 cites W2106327881 @default.
• W4385476503 cites W2772058283 @default.
• W4385476503 cites W2900786796 @default.
• W4385476503 cites W3010265999 @default.
• W4385476503 cites W3027587114 @default.
• W4385476503 cites W3047145162 @default.
• W4385476503 cites W3094065587 @default.
• W4385476503 cites W3159964039 @default.
• W4385476503 cites W3161005452 @default.
• W4385476503 cites W4282044607 @default.
• W4385476503 cites W4288074682 @default.
• W4385476503 doi "https://doi.org/10.1002/cncr.34964" @default.
• W4385476503 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37530385" @default.
• W4385476503 hasPublicationYear "2023" @default.
• W4385476503 type Work @default.
• W4385476503 citedByCount "1" @default.
• W4385476503 crossrefType "journal-article" @default.
• W4385476503 hasAuthorship W4385476503A5010518603 @default.
• W4385476503 hasAuthorship W4385476503A5022611419 @default.
• W4385476503 hasAuthorship W4385476503A5027746254 @default.
• W4385476503 hasAuthorship W4385476503A5033483931 @default.
• W4385476503 hasAuthorship W4385476503A5034299376 @default.
• W4385476503 hasAuthorship W4385476503A5035939033 @default.
• W4385476503 hasAuthorship W4385476503A5037999437 @default.
• W4385476503 hasAuthorship W4385476503A5042712372 @default.
• W4385476503 hasAuthorship W4385476503A5048170384 @default.
• W4385476503 hasAuthorship W4385476503A5050243008 @default.
• W4385476503 hasAuthorship W4385476503A5050932223 @default.
• W4385476503 hasAuthorship W4385476503A5077916842 @default.
• W4385476503 hasAuthorship W4385476503A5080548972 @default.
• W4385476503 hasAuthorship W4385476503A5082008325 @default.
• W4385476503 hasAuthorship W4385476503A5084241424 @default.
• W4385476503 hasAuthorship W4385476503A5086814670 @default.
• W4385476503 hasAuthorship W4385476503A5090145105 @default.
• W4385476503 hasAuthorship W4385476503A5091533961 @default.
• W4385476503 hasBestOaLocation W43854765031 @default.
• W4385476503 hasConcept C119060515 @default.
• W4385476503 hasConcept C126322002 @default.
• W4385476503 hasConcept C141071460 @default.
• W4385476503 hasConcept C142724271 @default.
• W4385476503 hasConcept C144301174 @default.
• W4385476503 hasConcept C2776694085 @default.
• W4385476503 hasConcept C2777506904 @default.
• W4385476503 hasConcept C2777532014 @default.
• W4385476503 hasConcept C2777547418 @default.
• W4385476503 hasConcept C2777793932 @default.
• W4385476503 hasConcept C2778239845 @default.
• W4385476503 hasConcept C2778256501 @default.
• W4385476503 hasConcept C2778629024 @default.
• W4385476503 hasConcept C2779217266 @default.
• W4385476503 hasConcept C2909636867 @default.
• W4385476503 hasConcept C2910096961 @default.
• W4385476503 hasConcept C38180746 @default.
• W4385476503 hasConcept C50382708 @default.
• W4385476503 hasConcept C71924100 @default.
• W4385476503 hasConceptScore W4385476503C119060515 @default.
• W4385476503 hasConceptScore W4385476503C126322002 @default.
• W4385476503 hasConceptScore W4385476503C141071460 @default.
• W4385476503 hasConceptScore W4385476503C142724271 @default.
• W4385476503 hasConceptScore W4385476503C144301174 @default.
• W4385476503 hasConceptScore W4385476503C2776694085 @default.
• W4385476503 hasConceptScore W4385476503C2777506904 @default.
• W4385476503 hasConceptScore W4385476503C2777532014 @default.
• W4385476503 hasConceptScore W4385476503C2777547418 @default.
• W4385476503 hasConceptScore W4385476503C2777793932 @default.
• W4385476503 hasConceptScore W4385476503C2778239845 @default.
• W4385476503 hasConceptScore W4385476503C2778256501 @default.
• W4385476503 hasConceptScore W4385476503C2778629024 @default.
• W4385476503 hasConceptScore W4385476503C2779217266 @default.
• W4385476503 hasConceptScore W4385476503C2909636867 @default.
• W4385476503 hasConceptScore W4385476503C2910096961 @default.
• W4385476503 hasConceptScore W4385476503C38180746 @default.
• W4385476503 hasConceptScore W4385476503C50382708 @default.
• W4385476503 hasConceptScore W4385476503C71924100 @default.
• W4385476503 hasLocation W43854765031 @default.
• W4385476503 hasLocation W43854765032 @default.

• next